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HER2Abstract Identiﬁcation of metastatic potential of breast cancer cells is necessary for proper man-
agement of this disease. This work aimed to estimate likelihood of axillary lymph node (ALN)
involvement in breast cancer patients based on human epidermal growth factor receptor 2
(HER2) expression. Primary tumors of 317 breast cancer patients were evaluated for estrogen
receptor (ER), progesterone receptor (PR) and HER2 expression by immunohistochemistry. The
validity of these molecules to predict ALN metastasis was measured statistically and compared
to predictive effect of other clinicopathological parameters. ER, PR and HER2 expression was
detected in 75.7%, 73.2% and 19.9% of tumors, respectively. Although increased tumor size and
grade, ER and PR negativity and HER2 positivity were strong indicators of ALN metastasis on
univariate analyses, only tumor size and HER2 expression were independent predictors of ALN
involvement on multivariate analysis. ROC curve showed a strong validity of the model using these
two parameters to predict ALN status (AUC 0.86; p< 0001). HER2-rich, luminal B and triple neg-
ative tumors had 6.87, 6.32 and 3.58 times increased risk of metastasis compared to luminal A
tumors; respectively. HER2 expression in pT1 and pT2 tumors raised the risk of ALN metastasis
by 7.7 and 7.6 times, respectively and grade 1 and 2 tumors that expressed HER2 were 16.0 and
7.8 times more likely to have ALN metastasis, respectively. To conclude, HER2 expression is asso-
ciated with a signiﬁcant rise of metastatic potential of breast cancer cells and could be a strong indi-
cator of regional and distant metastasis of breast cancer.
 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Breast cancer is still the most frequent malignant tumor in
women worldwide with nearly 1.7 million new cases diagnosed
in 2012, accounting for 25% of all new female cancer cases [1].
In Egypt, the rate of breast cancer is higher than the worldwide
records representing 32.04% of female cancers diagnosed dur-
ing 2008–2011 [2]. More importantly; it has been reported that
49.7% of the Egyptian patients have regional spread at the
220 A.R.H. Ahmedtime of diagnosis and 11.9% of them have distant metastasis
[3].
Breast cancer is a heterogeneous disease with different
molecular subtypes, cellular composition, clinical behavior
and response to treatment. Hence, pathological features such
as tumor size, tumor grade, nodal involvement and hormone
receptor status are essential for management and prognosis
of this disease. Axillary lymph node (ALN) status is the best
independent prognostic factor and is essential for treatment
planning of breast cancer patients. Selection of type and inten-
sity of neo-adjuvant and adjuvant chemotherapy of breast can-
cer is based mainly on ALN status and number of involved
lymph nodes [4]. Excision of the primary tumor with ALN dis-
section has been the standard surgical treatment of breast can-
cer. However, dissection of ALN is commonly associated with
local complication of the related upper limb including lym-
phedema, impaired shoulder movement, pain and numbness
[5]. The need for ALN dissection has been constantly reduced
because of the introduction of sentinel lymph node biopsy.
However; sentinel lymph node biopsy is still an invasive proce-
dure and could be associated with a risk of missed nodal
involvement and low sensitivity particularly in cases with
micro-metastasis [6].
Several studies have been conducted to predict ALN metas-
tasis in order to select patients unlikely to get beneﬁt from
ALN dissection. Size, grade and micro-vessel density of the
primary tumors were stated to be independent predictors to
signify ALN metastasis [7,8]. In addition, several molecules
including estrogen receptor (ER), progesterone receptor (PR)
and Ki-67 had been shown to have a predictive validity of
nodal metastasis of breast cancer [9]. Among molecules that
raised much attention as a possible prognostic marker is epi-
dermal growth factor receptor 2; also known as HER2/neu
or c-erbB-2. HER2 is a proto-oncogene that encodes a trans-
membrane receptor with a constitutive tyrosine kinase activity
involved in cellular proliferation, differentiation, migration,
and apoptosis. It is overexpressed due to gene ampliﬁcation
in 15–30% of human breast cancers [10]. In his review, Ross
et al. [11] reported that HER2 ampliﬁcation or overexpression
was associated with poor outcome in patients with ALN
metastases, but not in patients with tumor-negative lymph
nodes. In this study, the validity of HER2 to predict ALN
metastasis of breast cancer was evaluated and compared to
other established predictive clinical and pathological
parameters.
Materials and methods
Patients and samples
Ethical permission for this study was obtained from Ethics
Committee, Faculty of Medicine, Sohag University. All breast
cancer cases treated surgically at Sohag Cancer Institute or
Sohag University Hospital during January 2014 to December
2015 were included in this study. The main inclusion criterion
was surgical treatment by either radical mastectomy or conser-
vative breast surgery with complete ALN dissection. Patients
were excluded from the study if the primary tumor was previ-
ously excised, if the tumor was locally advanced (stage 4), if the
patient underwent only ALN sampling, if they had distant
metastasis at time of diagnosis and if they received pre-operative neo-adjuvant therapy. Formalin-ﬁxed parafﬁn-
embedded tissue blocks of 317 tumors were retrieved for the
study. The patients were treated with modiﬁed radical mastec-
tomy (n= 207) or conservative breast surgery (n= 110) with
complete dissection of ALNs. Clinical data were obtained
from the patient’s clinical ﬁles and sections from primary
tumors and ALNs were reviewed for evaluation of histopatho-
logical ﬁndings. The tumors were graded according to the
Bloom and Richardson scheme [12] and the tumor size was
the maximum tumor diameter. The pathological stage of the
primary tumor was classiﬁed according to maximum diameter
into pT1 for tumors up to 2 cm, pT2 for tumors of 2.1–5 cm
and pT3 for tumors more than 5 cm [13].
Immunohistochemistry
Four micrometer-thick sections were de-deparafﬁnized in
xylene and rehydrated in down-graded alcohols before wash-
ing thoroughly in running water. The sections were incubated
in dual endogenous enzyme blocking solution (Dako Code
K4065) for 10 min to block endogenous peroxidase activity
followed by washing in running water. Antigen unmasking
was by boiling the sections in 10 mM citrate buffer, pH 6.0
in a microwave at high power for 2  5 min; followed by cool-
ing down to room temperature for 30 min. The sections were
washed in phosphate-buffered saline (PBS) pH 7.6 before
incubation with either mouse monoclonal anti-human ER-a
(Dako, clone 1D5, code M7047), mouse monoclonal anti-
human PR (Dako, clone 636, code M3569) or rabbit poly-
clonal anti-human c-erbB-2 protein (Dako, code A0485) for
30 min at room temperature. After washing twice in PBS, the
sections were incubated with Peroxidase labeled polymer con-
jugated to goat anti-mouse and goat anti-rabbit immunoglob-
ulin (Dako, code K4065) for 30 min at room temperature. The
sections were washed with 0.5% PBS and exposed to a freshly
prepared 3,30-diaminobenzidine tetrahydrochloride (DAB)
solution (Dako, code K4065) for 5–10 min to yield an insol-
uble brown deposit. Finally, the sections were counterstained
with hematoxylin, dehydrated and mounted as usual. Replace-
ment of the primary antibodies with TBS served as negative
controls for the IHC process.
Immunohistochemistry scoring and intrinsic subtyping of breast
cancer
The expression of ER and PR was scored according to Allred
scheme which is based on summation of proportion of positive
cells and staining intensity [14]. Only nuclear immunoreaction
of the invasive tumor component was evaluated and the ﬁnal
score was 0 or 2–8. Allred score 0 or 2 were classiﬁed as hor-
mone receptor negative while Allred score 3–8 were considered
as hormone receptor positive and this is concordant to recom-
mendations of the American society of clinical oncology/Col-
lege of American Pathologists (ASCO/CAP) that consider
expression of hormone receptors to be negative if less than
1% of tumor cells was immunoreactive [15]. HER2 immunore-
action was evaluated in only invasive tumor cells and scored
according to the updated ASCO/CAP recommendations [16].
This is a semi-quantitative scoring system based on intensity
of cell membrane immunoreaction and the percentage of mem-
brane positive cells, giving a score range of 0–3+. Only score 3
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1+ tumors were considered as HER2-negative. Equivocal
cases (Score 2+) were excluded from the study as conﬁrmation
of HER2 gene ampliﬁcation with ﬂorescence in situ hybridiza-
tion (FISH) was not available in the institution. According to
expression status of ER, PR and HER2 molecules; tumors
included in this study were categorized into four groups: lumi-
nal A for ER+/PR+/HER2 tumors, luminal B for ER+/
PR/HER2, ER/PR+/HER2 and ER and/or PR+/
HER2+ tumors, HER2-enriched (non-luminal) for ER/
PR/HER2+ tumors and triple negative for ER-/PR-/
HER2- tumors [17].
Statistical analysis
The commercially available statistical software IBM-SPSS
(version 22 for windows; IBM Inc.) was used for data analysis.
A p-value of less than 0.05 was considered as statistically sig-
niﬁcant. Chi-square test (v2) was performed to compare the
rates of ALN metastasis between different study groups. The
association of two continuous variables was analyzed by
Spearman’s rho test and the association between continuous
and grouped variables were analyzed by either Mann–Whitney
U or Kruskal–Wallis test. Univariate binary logistic regression
analysis was performed to assess risk factors for ALN metas-
tasis and to calculate odds ratio and 95% conﬁdence intervals
(CI) for probabilities of ALN metastasis. Variables with
p-values <0.05 in univariate analyses were included in a mul-
tivariate regression analysis using a foreword selection proce-
dure to identify the independent risk factors of ALN
metastasis and to select the best predictive model of nodal
metastasis. The receiver operating characteristic (ROC) curve
was constructed and the area under the curve (AUC) was used
to assess the predictive accuracy of the model.Results
Three hundred and seventeen women with breast cancer were
included in this study. The age ranged between 24 and 77 years
with a mean (±SD) of 50.32 (±10.67) years and a median of
51.00 years. Nearly half of the investigated cases (48.27%)
were aged 50 years or younger and more than one fourth of
them (25.56%) were pre-menopausal. The tumor size ranged
between 1.00 and 11.00 cm with mean (±SD) and median val-
ues of 3.72 (±1.75) cm and 3.00 cm, respectively. Based on
their sizes, the tumors were classiﬁed as pT1, pT2 and pT3
in 80, 187 and 50 cases, respectively. Ninety percent of the
investigated tumors (n= 284) were invasive duct carcinoma,
not otherwise speciﬁed (IDC NOS) while invasive lobular,
medullary, papillary, mucinous, tubular, and cribriform sub-
types were recorded in 13, 12, 3, 2, 2, and 1 cases, respectively.
The majority of tumors were grade II, representing 74.1%
while grade I and III occurred in 6.3% and 19.6%, respec-
tively. ALN metastasis was conﬁrmed histologically in nearly
half of the investigated cases (n= 157) and the number of
involved lymph nodes ranged between 1 and 32 with a median
number of 6.
Expression of ER and PR was detected in 240 (75.7%) and
232 (73.2%) tumors, respectively and overexpression of HER2
protein (score 3+) was evident in 63 (19.9%) of the investi-
gated cases. Diffuse strong expression of ER and PR (Allredscore 8) was recorded in 181 and 173 cases, respectively. The
expression of ER and PR was speciﬁcally nuclear
(Fig. 1A and B) while expression of HER2 was demonstrated
as a continuous membranous immunoreaction (Fig. 1C). The
tumor stroma showed always negative expression of the three
molecules. Based on combined expression of ER, PR and
HER2 molecules, 192 of the tumors were classiﬁed as luminal
type A while luminal type B, HER2-rich and triple negative
tumors were recorded in 56, 23 and 46 cases, respectively.
Among the luminal B tumors; 16 were luminal/HER2-
negative and 40 were luminal/HER2-positive cases.
Among different investigated parameters of breast cancer
(Table 1); increase of tumor size and grade and positive expres-
sion of HER2 were strongly associated with ALN metastasis.
Alternatively; positive expression of both ER and PR seems
to reduce the probability of ALN involvement. Nonetheless,
the number of involved lymph nodes was signiﬁcantly higher
in large sized tumor (r= 0.575; p< 0.0001), in high grade
tumors (Kruskal–Wallis test, p< 0.0001), in HER2-positive
tumors (Mann–Whitney U test, p< 0.0001), in ER-negative
tumors (Mann–Whitney U test, p= 0.008) and in PR-
negative tumors (Mann–Whitney U test, p< 0.001). Tipple
negative, HER2-rich and luminal B breast cancer had signiﬁ-
cantly higher rates of ALN metastasis [v2 (3) = 46.4,
p< 0.0001].
According to combined expression of steroid and HER2
receptors, breast cancer would fall into one of eight possible
categories: ER+/PR+/HER2+, ER+/PR+/HER2, ER
+/PR/HER2+, ER+/PR/HER2, ER/PR+/HER2
+, ER/PR+/HER2, ER-/PR-/HER2+ and ER/PR/
HER2. These eight categories were presented in this study
in 33, 192, 3, 12, 4, 4, 23 and 46 cases, respectively. Among
these categories; the triple positive and ER/PR/HER2+
breast cancer subtypes had frequent ALN metastasis while
ER+/PR+/HER2 breast cancer was the least likely to
metastasize (Table 2). In the same context, luminal B and
HER2-rich breast cancer; both of which showed frequent over-
expression of HER2 had 6.32 and 6.87 times increase risk of
ALN metastasis; respectively compared to luminal A breast
cancer which is HER2 negative while triple negative tumors
had only 3.58 times increased risk of metastasis (Table 3).
These ﬁndings reﬂect that HER2 overexpression could be the
most important deﬁning factor for ALN metastasis among
the three molecules.
The validity of HER2 expression to predict ALN metastasis
was compared to other pathological parameters of breast can-
cer. Although increased tumor size and grade, ER and PR neg-
ativity and HER2 positivity were strong indicators of ALN
metastasis on univariate regression analyses, only tumor size
and HER2 expression were independent strong predictors of
ALN involvement on multivariate regression analysis
(Table 4). ROC curve showed a strong validity of the model
using these two parameters in predicting the status of ALN
(AUC 0.86; SE 0.021; CI 0.82–0.90, p< 0001, Fig. 2). This
percentage was not improved when tumor grade was included
in the predictive model.
To neutralize the effect of tumor size and grade, the associ-
ations of HER2 expression with ALN metastasis in pT1, pT2,
grade 1 and grade 2 tumors were separately evaluated. There
were signiﬁcant associations of HER2 expression and ALN
metastasis in early stages and low grades breast cancer
(Fig. 3). Among pT1 tumors, HER2-positivity was associated
Figure 1 Nuclear expression of ER (A) and PR (B) and membranous expression of HER2 (C) in breast cancer. Magniﬁcation is 400
for A, B and C.
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32.7, p= 0.005) and among pT2 tumors, HER2 expression
raised risk of ALN metastasis by 6.7 times (95% CI = 2.5–
18.1, p< 0.0001). Similarly; grade 1 tumors that expressed
HER2 were at least 1.2 times more likely to have ALN metas-
tasis (95% CI = 1.2–200, p= 0.032) and grade 2 tumors that
expressed HER2 were 7.8 times more likely to have nodal
metastasis (95% CI = 3.4517.0, p< 0.0001).
Discussion
Breast cancer is the main leading cause of cancer deaths among
Egyptian women and worldwide [2,3]. It is not the primary
tumor; but metastases that are the main cause of death in these
patients. ALN involvement is the main route for spread of
breast carcinoma. Pre-operative identiﬁcation of patients with
high risk of ALN metastasis would enable surgeons and oncol-
ogists to plan treatment strategies to individual patients. In a
study that included 3747 cases of breast cancer in Egypt; Nouhet al. [8] demonstrated that tumor size and old age signiﬁcantly
raised the likelihood of ALN metastasis. In this study; the
validity of ER, PR and HER2 expression to predict metastatic
potential of breast cancer in Egyptian women was evaluated
and compared to other clinical and pathological parameters.
Categorization of breast cancer according to ER, PR and
HER2 expression was also provided.
Fifty-one of the investigated cases (16.1%) had pT3 tumor
stage and ALN metastasis was detected in 49.5% of which
36.3% and 29.3% were classiﬁed as pN2 and pN3 nodal stage,
respectively. Weak screening programs, non-systematic health
insurance and cultural and socioeconomic considerations could
be explanatory reasons for the late stage at diagnosis of breast
cancer among Egyptian women. The rates of ER, PR and
HER2 expression in this study and the rates of intrinsic subtypes
of breast cancer based on expression of these threemolecules are
comparable to records of previous literature [13,18,19].
According to this study; increased tumor size, high tumor
grade, negative expression of hormone receptors and positive
expression of HER2 were strongly associated with ALN
Table 1 Correlation of clinical and pathological parameters with axillary lymph node status.
Variable Statistic Lymph node status All p value
Negative
N= 160
Positive
N= 157
Age (years) Mean (SD)
Median
50.59 (10.77)
52.00
50.04 (10.60)
50.00
50.32 (10.67)
51.00
0.713**
Menopausal status
Pre-menopausal N (%) 44 (27.5) 37 (23.6) 81 (25.6) 0.609*
Peri-menopausal N (%) 28 (17.5) 33 (21.0) 61 (19.2)
Post-menopausal N (%) 88 (55.0) 87 (55.4) 175 (55.2)
Pathology
IDC NOS N (%) 140 (87.5) 144 (91.7) 284 (89.6) 0.219*
Other types N (%) 20 (12.5) 13 (8.3) 33 (10.4)
Tumor size (cm) Mean (SD)
Median
2.82 (1.29)
3
4.64 (1.67)
4.50
3.72 (1.75)
3.00
0.0001**
pT stage
pT1 N (%) 67 (41.9) 13 (8.3) 80 (25.2)
pT2 N (%) 87 (54.3) 100 (63.7) 187 (59.0) 0.0001*
pT3 N (%) 6 (3.8) 44 (28.0) 50 (15.8)
Grade
I N (%) 13 (8.1) 7 (4.5) 20 (6.3) 0.0001*
II N (%) 136 (85.0) 99 (63.0) 235 (74.1)
III N (%) 11 (6.9) 51 (32.5) 62 (19.6)
ER
Negative N (%) 25 (15.6) 52 (33.1) 77 (24.3) 0.0001*
Positive N (%) 135 (84.4) 105 (66.9) 240 (75.7)
PR
Negative N (%) 27 (16.9) 58 (36.9) 85 (26.8) 0.0001*
Positive N (%) 133 (83.1) 99 (63.1) 232 (73.2)
HER2
Negative N (%) 149 (93.1) 105 (66.9) 254 (80.1) 0.0001*
Positive N (%) 11 (6.9) 52 (33.1) 63 (19.9)
Molecular subtype
Luminal A N (%) 126 (78.8) 66 (42.0) 192 (60.5) 0.0001*
Luminal B N (%) 13 (8.1) 43 (27.4) 56 (17.7)
HER2-rich N (%) 5 (3.1) 18 (11.5) 23 (7.3)
Triple negative N (%) 16 (10.0) 30 (19.1) 46 (14.5)
Chi square test* was used for categorical variables and Spearman rho correlation coefﬁcient test was used for quantitative variables**. IDC NOS
states for invasive duct carcinoma, not otherwise speciﬁed, pT for pathological stage, ER for estrogen receptor, PR for progesterone receptor
and HER2 refers to human epidermal growth factor receptor 2.
Table 2 Risk of axillary lymph node metastasis in breast cancer subtypes deﬁned by ER, PR and HER2 expression.
Breast cancer subtype Total number Number (%) of involved axillary lymph nodes p value Odds ratio 95% Conﬁdence interval
Lower Upper
ER+/PR+/HER2 192 66 (34.4%) Reference
ER+/PR+/HER2+ 33 30 (90.9%) 0.000 19.091 5.616 64.898
ER+/PR/HER2 12 8 (66.7%) 0.034 3.818 1.109 13.150
ER/PR+/HER2 4 1 (25.0%) 0.698 .636 .065 6.238
ER+/PR/HER2+ 3 1 (33.3%) 0.970 .955 .085 10.722
ER/PR+/HER2+ 4 3 (75.0%) 0.134 5.727 .584 56.144
ER/PR/HER2+ 23 18 (78.3%) 0.000 6.873 2.442 19.340
ER/PR/HER2- 46 30 (65.5%) 0.000 3.580 1.821 7.037
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Table 3 Risk of axillary lymph node metastasis among different intrinsic breast cancer subtypes:
Breast cancer subtype Total number Number (%) of involved axillary lymph nodes p value Odds ratio 95% Conﬁdence interval
Lower Upper
Luminal A 192 66 (34.4%) Reference
Luminal B 56 43 (76.8%) .000 6.32 3.17 12.57
HER2-rich 23 18 (78.3%) .000 6.87 2.44 19.34
Triple negative 46 30 (65.2%) .000 3.58 1.82 7.04
Table 4 Univariate and multivariate regression analysis of factors associated with axillary lymph node metastasis.
Parameter Univariate regression co-eﬃcient (95% CI) p value Multivariate regression co-eﬃcient (95% CI) p value
Increased tumor size 2.568 (2.057–3.207) 0.000 2.351 (1.852–2.984) 0.000
Increase tumor grade
Grade II 2.038 (0.711–5.845) 0.185 1.194 (0.341–4.179) 0.781
Grade III 14.84 (4.362–50–49) 0.000 6.295 (1.473–26.91) 0.013
Negative ER expression 2.674 (1.557–4.593) 0.000 0.935 (0.306–2.854) 0.805
Negative PR expression 2.886 (1.706–4.881) 0.000 1.545 (0.520–4.592) 0.434
Positive HER2 expression 6.708 (3.342–13.46) 0.000 5.503 (2.433–12.45) 0.000
1 - Specificity
1.00.80.60.40.20.0
Se
ns
iti
vi
ty
1.0
0.8
0.6
0.4
0.2
0.0
AUC 0.86 (CI 0.82–0.90), p<0001
Figure 2 ROC curve for predicting axillary lymph node metas-
tasis of breast cancer using tumor size and status of HER2
expression.
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lymphovascular invasion are strong predictors of ALN metas-
tasis, disease free survival and overall survival of breast cancer
[20]. Although ER and PR are well established strong predic-
tors of hormonal therapy of breast cancer patients; their valid-
ity to predict ALN metastasis is controversial. Few reports
referred to a negative association of hormone receptor expres-
sion and ALN metastasis [21] while others reported that
expression of ER and PR was associated with a relativeincreased risk of metastasis [22]. Still other studies showed
no relationship of ER or PR to ALN metastasis [23,24]. In this
study, the expression of both ER and PR was predictive of
absent nodal metastasis on univariate but not multivariate
models which suggests a weak validity of both molecules in
comparison to other parameters.
HER2 expression was a strong predictive factor of ALN
metastasis on univariate regression analysis and it was the sec-
ond strongest factor after tumor size in multivariate analysis
(Table 4). In the same context, HER2-rich breast cancer sub-
type had the highest risk of ALN metastasis compared to lumi-
nal A tumors (Table 3) followed by luminal B subtype which
included a considerable number of HER2-positive cases.
Among luminal B cases; HER2-positive cases showed a signif-
icant association with ALN metastasis compared to HER2-
negative cases (Chi-square = 5.29, p= 0.021). Moreover;
HER2 expression was strongly associated with ALN metasta-
sis in early stages and low grades breast cancer cases (Fig. 3).
Taken together; these data imply that whenever expressed,
HER2 is associated with a signiﬁcant higher risk of ALN
metastasis of breast cancer regardless of tumor size, grade,
hormonal status or intrinsic subtype. In separate large studies;
luminal/HER2 and HER2-enriched intrinsic subtypes had
higher tumor and nodal stage, frequent regional recurrence,
early relapse rates and worse overall survival compared to
other subtypes [25,26]. In the same context, several studies
showed that triple negative breast cancer which is a distinctive
subtype with aggressive clinical course and poor outcome had
signiﬁcantly lower rates of ALN positivity compared to
HER2-positive breast cancer subtypes [9,27,28]. Among the
eight possible combinations of ER, PR and HER2 expression
status; the triple positive and ER/PR/HER2+ breast can-
cer subtypes had 19.1 and 6.9 times increased risk of ALN
metastasis; respectively compared to ER+/PR+/HER2
tumors which was the most frequent subtype in this study
and the least likely to have ALN metastasis. This is concordant
Figure 3 Association of HER2 expression with axillary lymph node metastasis in pT1 (A), pT2 (B), grade 1 (C) and grade 2 (D) breast
cancer.
HER2 expression predicts breast cancer nodal metastasis 225with previous literature [21,22] and conﬁrms that HER2 over-
expression is an important driver for breast cancer cells to
metastasize. Accordingly, expression status of HER2 could
be valuable to predict metastatic potential of breast cancer
cells. Multivariate regression analysis of different clinical and
pathological characteristics of breast cancer showed that com-
bination of tumor size and HER2 expression status had the
best performance to predict ALN metastasis. The model using
these two parameters showed a strong predictive validity of
ALN metastasis on ROC curve analysis with AUC of 86%
(CI: 82–90%, p< 0.0001, Fig. 2). This prediction scheme
could be valuable to reduce the need for complete ALN dissec-
tion and to properly select patients with high risk of distant
metastasis for subsequent targeted therapy.The main limitation of this study was subtyping of luminal
breast cancer into A and B subtypes based on expression status
of PR but not on expression status of the proliferation marker;
Ki-67. However; recent studies have reported that absence of
PR expression is associated with poor prognosis of breast can-
cer and proposed that PR-negative breast cancer should be
classiﬁed as luminal B subtype [29,30]. Providing initial infor-
mation about the intrinsic subtypes of breast cancer in Upper
Egypt was one of the strong points of this study.
Conclusion
Breast cancer is no longer a single but rather a heterogeneous
disease with diverse clinical, biological, pathological and
226 A.R.H. Ahmedmolecular features. Risk assessment of metastatic potential of
this disease is important for therapeutic and prognostic impli-
cations. HER2 but not ER or PR expression was strongly
associated with increased risk of breast cancer metastasis irre-
spective to tumor stage and grade and it had a strong validity
to predict ALN metastasis in both univariate and multivariate
regression analyses. The model using tumor size and HER2
expression status was able to accurately predict ALN metasta-
sis with AUC of 86% at ROC curve analysis.Conflict of interest
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